Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 1;204(1):94-102.
doi: 10.1093/infdis/jir209.

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study

Nicolas Wentzensen  1 , Ana Cecilia Rodriguez, Raphael Viscidi, Rolando Herrero, Allan Hildesheim, Arpita Ghosh, Jorge Morales, Sholom Wacholder, Diego Guillen, Mario Alfaro, Mahboobeh Safaeian, Robert D Burk, Mark Schiffman
Affiliations

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study

Nicolas Wentzensen et al. J Infect Dis. .

Abstract

Background: A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18.

Methods: In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period.

Results: cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94).

Conclusions: Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials diagram describing the sample selection from (A) the complete Guanacaste Natural History Study (NHS) and (B) the 1100-women age-stratified subcohort.
See this image and copyright information in PMC

References

    1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50. - PubMed
    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. - PubMed
    1. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16–S22. - PubMed
    1. Roden RB, Weissinger EM, Henderson DW, et al. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol. 1994;68:7570–4. - PMC - PubMed
    1. Roden RB, Armstrong A, Haderer P, et al. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol. 1997;71:6247–52. - PMC - PubMed

Publication types